anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent research shows that sleep could play a novel role in preventing obesity and long-term morbidity. Population studies find that too little sleep predicts the development of obesity and experimental studies show that short sleep increases dietary intake without increasing physical activity. Sleep may be a particularly potent intervention target for adolescents. During adolescence, inadequate sleep is very common, obesity rates are rising most, non-sleep-oriented obesity prevention programs have had least success, and young people can develop enduring dietary patterns that set the stage for life-long obesity and health risk. The investigators' lab has shown both the promise of longer sleep for adolescents and a critical knowledge gap. That lab found that extending adolescents' sleep via earlier bedtimes impressively reduced caloric intake for early chronotypes ("Morning Larks"; who prefer early bed- and rise times), but not late chronotypes ("Night Owls"; who prefer late bed- and rise times). The effect was not only statistically strong, but at roughly 400 calories difference per day, could add up to major shifts in body weight over time. Beyond calorie counts, there was a similar discrepancy in the glycemic load consumed by Larks and Owls after sleep extension, and glycemic load has been independently linked to long-term morbidity. The investigators assert that the discrepancy in how Larks and Owls responded to longer sleep is due to circadian misalignment: a mismatch between the timing of external sleep-wake demands and internal biological clock. They investigators propose that, for adolescent Owls, an early-to-bed intervention induces misaligned sleep timing that counters the benefits of longer sleep duration. In adults, severe circadian misalignment dramatically increases the risk for obesity, and even modest misalignment is linked to higher caloric intake. If a cause-effect relationship holds in adolescence, common sleep advice emphasizing earlier bedtimes might waste limited resources or even do harm for Owls. In contrast, an approach that considers chronotype might capitalize on the potent effect of improved sleep that has been shown for Larks. The current protocol reflects a novel experimental study in which 124 healthy 14-18-year-olds (62 Owls and 62 Larks) complete a 3-week trial involving periods of sleep restriction and sleep extension, in which the extension periods are randomly assigned to be aligned vs. misaligned relative to chronotype. Focusing independently on caloric intake and glycemic load, investigators will assess the dietary effect of sleep extension when it is well-timed versus poorly-timed relative to adolescents' internal clocks. The study will test a causal model in which sleep timing plays an important role in promoting or negating the benefits of sleep extension.
These products are sterile, nonpyrogenic solutions of electrolytes in water for injection intended only for sterile irrigation, washing, rinsing and dilution purposes.

Each 100 mL of 0.9% Sodium Chloride Irrigation, USP contains: Sodium chloride 900 mg; pH 5.6 (4.5 to 7.0). May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The solution is isotonic (308 mOsmol/liter, CALC.) and has the following electrolyte content (mEq/liter): Na+ 154; Cl− 154.

These irrigations contain no bacteriostat, antimicrobial agent or added buffer and are intended only for use as single-dose or short procedure irrigation. When smaller volumes are required the unused portion should be discarded.

Each of these irrigations may be classified as a sterile irrigant, wash, rinse, diluent and pharmaceutical vehicle.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

Water for Injection, USP is chemically designated H2O.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. 

The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The container requires no vapor barrier to maintain the proper drug concentration.

Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
BACKGROUND: The use of morphine in clinical medicine is severely constrained by tolerance. Therefore, it is essential to examine pharmacological therapies that suppress the development of morphine tolerance. Amiloride suppressed the expression of inflammatory cytokines by inhibiting microglial activation. Microglia play a crucial role in the establishment of morphine tolerance. Thus, we anticipated that amiloride might suppress the development of morphine tolerance. During this investigation, we assessed the impact of amiloride on mouse morphine tolerance.
METHODS: Mice received morphine (10 mg/kg, s.c.) twice daily with intrathecally injected amiloride (0.3 μg/5 μl, 1 μg/5 μl, and 3 μg/5 μl) for nine continuous days. To assess morphine tolerance, mice underwent the tail-flick and hot plate tests. BV-2 cells were used to investigate the mechanism of amiloride. By using Western blotting, real-time PCR, and immunofluorescence labeling methods, the levels of acid-sensing ion channels (ASICs), nuclear factor kappa B (NF-kB) p65, p38 mitogen-activated protein kinase (MAPK) proteins, and neuroinflammation-related cytokines were determined.
RESULTS: The levels of ASIC3 in the spinal cord were considerably increased after long-term morphine administration. Amiloride was found to delay the development of tolerance to chronic morphine assessed via tail-flick and hot plate tests. Amiloride reduced microglial activation and downregulated the cytokines IL-1β and TNF-a by inhibiting ASIC3 in response to morphine. Furthermore, amiloride reduced p38 MAPK phosphorylation and inhibited NF-κB expression.
CONCLUSIONS: Amiloride effectively reduces chronic morphine tolerance by suppressing microglial activation caused by morphine by inhibiting ASIC3.
Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
Embodiments of synchronizing the device clock in wound monitoring and/or therapy systems are disclosed. In some cases, a wound monitoring and/or therapy device can maintain a device clock, which can be set to a network time obtained from a network or internal time associated with a time set during configuration of the device. The device can selectively set the device clock to the network time in response to obtaining the network time and determining that the device clock is set to the internal time. In some cases, a remote computing device can receive a record transmitted by a wound monitoring and/or treatment device. The record can include a first set of operational parameters associated with monitoring and/or provision of treatment by the device and a first timestamp indicating a time of obtaining at least some operational parameters. The remote computing device can synchronize the first timestamp with network time.
FIELD: medicine. SUBSTANCE: invention relates to development of an agent of vegetable origin eliciting immunostimulating action. Invention proposes amaranthus seeds oil as the immunomodulating agent. Proposed immunostimulating agent shows the distinctly expressed immunostimulating effect and can be used for correction of immunodeficiency states in treatment of patients with diseases of different etiology: cardiovascular and oncological diseases, metabolic disturbances, erosion-ulcerous damages of gastroenteric tract, psoriasis, neurodermatitis. EFFECT: valuable medicinal properties of agent. 1 ex
PURPOSE:To obtain an effective remedy for kidney diseases and effective foods for recovery of kidney diseases with high safety containing dietary fibers prepared from the husk of food seeds as the active components. CONSTITUTION:Husks and shucks of corn, crops such as wheat bran, beans are powdered using a crusher and then passed through a sieve to prepare food fibers. The resultant food fibers are formed into a tablet, powder, granule, ampled liquid medicine, etc., and orally administrated. The above-mentioned food fibers may be also orally administrated without more processing. The administration of the above-mentioned fibers may be carried out in a form of foods prepared by addition thereof to all sorts of ingesta such as biscuit, candy, jelly, juice, soup, noodles or meat product. The does is preferably >=1g per day as the food fibers. The content of the food fibers is recommendably 10-100wt.% in a remedy for kidney diseases and the order of 1-60wt.% in ingesta.
Pelvic organ prolapse (POP) is a global health care issue that could have a significant impact on pelvic floor function and quality of life (QOL), while seldom having the potential to be life-threatening. Prevalence of POP increases with age. In women older than 80, 11% undergo a surgical procedure. The incidence of degenerative diseases and multiple co-morbidities increases with age, and advanced age is also associated with an increase in morbidity generally for gynecologic procedures. Furthermore, greater comorbidity beforehand can predispose patients to postoperative complications such as bleeding, hematoma, pain, infectious. As a result hospital stays are longer and the surgical results are compromised.

Surgical techniques should optimize functional results and minimize complications. In POP surgery, younger women are good candidates for sacrocolpopexy (SCP), because of the improved long term functional result, while women older than 80 may have a satisfactory outcome with fewer complication with a vaginal repair with mesh (VMR) or native tissue (NTR). The increasing prevalence of POP, and the increasing population of women aged 70-80 requires an evaluation of the appropriate surgical management since women in this age group may be candidates for all types of surgical repair.
1,132,318. Phenylacetic esters. J. R. GEIGY A.G. 29 March, 1967 [30 March, 1966], No. 14261/67. Heading C2C. New phenylacetic esters of the general formula (wherein R 1 , R 2  and R 4  each represent a C 1-4  alkyl or alkoxy group, a halogen atom up to atomic number 35 or a CF 3  group, or R 2  and R 4  may also represent H, R 3  represents H, a C 1-4  alkyl or alkoxy group or a halogen atom up to atomic number 35, R 5  and R 6  represent H, C 1-5  alkyl groups or benzyl groups, and R 7  represents a C 1-6  alkyl group or an aralkyl group with up to 3 carbon atoms in the alkylene portion) are prepared from the corresponding acid by known esterification methods, raised temperatures being avoided when the reaction medium is acid. Methods specified are reaction of the free acid with a diazoalkane in an inert organic solvent, with a 1,1-dialkoxy- or -diaralkoxy-trimethylamine in an inert solvent, with an alkanol or arylalkanol in the presence of 1,1-dineopentyloxytrimethylamine, or, at temperatures not above - 5 C., with an alkanol or arylalkanol and SOCl 2 , and reaction of a salt of the acid with an alkyl or aralkyl halide, sulphate or sulphonate. Phenylacetic acids employed as starting materials are prepared by the following processes: (1) hydrolysing the correspondingly substituted 1-phenyl-2-indolinones, which in turn are prepared as follows: (a) when R 5  and R 6  are H or R 5  is C 1-5  alkyl and R 6  is H, reacting an appropriately substituted diphenylamine with a 2-chloroalkanoyl chloride and heating the resulting 2 - chloro - N - phenylalkanoanilide with AlCl 3 ; (b) when one or both of R 5  and R 6  is or are C 1-5  alkyl or benzyl, converting a corresponding 1-phenyl-2-indolinone in which R 5  = R 6  = H to its mono- or di-Na compound by reaction with NaH or NaNH 2  in dimethylformamide and reacting the product with the corresponding amount of a C 1-5  alkyl or benzyl halide; (c) when R 5  is benzyl and R 6  is H, condensing a 1-phenyl-2-indolinone in which R 5  = R 6  = H with benzaldehyde and hydrogenating the resulting 1-phenyl-3-benzylidene-2-indolinone; (2) reducing a low alkyl ester of an appropriate N-phenylanthranilic acid to a substituted o-anilinobenzyl alcohol, boiling this with acetyl chloride to form a substituted α-chloro- N-phenyl-o-toluidine or a substituted α-chloro- N-phenylaceto-o-toluidide (depending on the nature of the substitution in the phenyl group), reacting the product with NaCN or KCN and hydrolysing the resulting α-cyano compounds. The preparation of the following starting materials is also described: 2,6-dichloro-N- phenyl - m - toluidine; 2,6 - dichlorodiphenylamine; N - (2,6 - dichlorophenyl) - acetanilide; 2,6,41 - trichlorodiphenylamine; N - (p - chlorophenyl) - 2,6 - dichloro - m - toluidine; 2,6 - dichloro - N - (p - methoxyphenyl) - m - toluidine. Therapeutic preparations for the treatment of inflammatory diseases comprise the esters of the general formula above in combination with an inert carrier and, optionally, further additives.
BACKGROUND: Advanced practice physiotherapy (APP) models of care have shown success in access, safety, satisfaction, and care quality for musculoskeletal pain conditions in various settings. Yet, there is a gap in defining competencies for physiotherapists to be the initial point of contact for people with chronic pain. This study aims to identify and agree upon the competencies necessary for a physiotherapist to fulfill the role of an APP in an interprofessional chronic pain clinic.
METHODS: Three focus groups were conducted using a Nominal Group Technique and a modified Delphi process. Consensus on the competency, defined as agreement by ≥ 75% of participants, was sought.
RESULTS: Twenty-three experts (17 healthcare providers and six individuals with chronic pain) participated in the focus group discussions. Twenty completed the follow-up Delphi surveys. Ten essential competencies for an APP role in interprofessional chronic pain clinics were identified and achieved consensus: 1) use an evidence-based approach to practice; 2) communicate effectively with the patient; 3) perform a comprehensive assessment; 4) determine pain-related diagnoses; 5) develop therapeutic relationships; 6) provide appropriate care; 7) support patients through transitions in care; 8) collaborate with members of the interprofessional team; 9) advocate for the needs of the patients; and 10) use a reflective approach to practice.
CONCLUSION: This study identified ten competencies essential for physiotherapists to fulfill an APP role within interprofessional chronic pain clinics. These competencies serve as a foundation for informing a training program and future research evaluating the effectiveness of the APP model in this setting.
disclosed herein is a novel composition comprising a purified cannabinoid and a purified terpene. In one embodiment, the composition comprises one or more purified cannabinoids. In one embodiment, the composition comprises a combination of one or more purified cannabinoids and one or more purified terpenes. In one embodiment, the composition comprises a non-naturally occurring proportion. In one embodiment, the composition comprises a non-naturally occurring concentration. In one embodiment, the composition comprises an unexpected and/or synergistic effect.
Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
Approximately 5-10% of all patients affected by COVID-19 develop severe respiratory distress. This has already involved hundreds of people in Ontario and thousands worldwide. In this situation, support with a mechanical ventilator is required. The first essential step to provide this support is to insert a breathing tube in the patent's trachea (windpipe), a process called 'endotracheal intubation' or more broadly, 'airway management'. While a fundamental lifesaving resource, endotracheal intubation in COVID-19 patents is a highly specialized procedure that carries risk both to patents and attending healthcare providers as follows. a) Clinicians involved in airway management for patients with coronaviruses are at extremely high risk of infection due to aerosol and droplet exposure during the procedure. b) Rapid administration of drugs that put the patent to sleep is usually required for prompt and safe endotracheal intubation. However, in physiologically compromised patents, life-threatening side-effects may occur, such as very low oxygen levels (in as many as 70% of patients), low blood pressure (18-22% of patients), and cardiac arrest (2%); these can significantly affect outcomes. No definitive data are presently available to accurately quantify the risk posed by such procedures to healthcare professionals and patents, nor the associated factors. We have developed a retrospective study reviewing data all airway management related SAEs in COVID 19 patients (between April and July 2020); hypoxemia, hypotension and cardiac arrest within 15 min of intubation. Additionally, we are going to prospectively interview Airway Management Team members that were involved in the airway management of COVID19 patients in the period described above, in order to assess whether they developed signs and symptoms and/or a confirmed COVID19 infection. This prospective interview component is starting in December 2020.
Limb apraxia is a motor disorder frequently observed following a stroke. Apraxic deficits are classically assessed with four tasks: tool use, pantomime of tool use, imitation, and gesture understanding. These tasks are supported by several cognitive processes represented in a left-lateralized brain network including inferior frontal gyrus, inferior parietal lobe (IPL), and lateral occipito-temporal cortex (LOTC). For the past twenty years, voxel-wise lesion symptom mapping (VLSM) studies have been used to unravel the neural correlates associated with apraxia, but none of them has proposed a comprehensive view of the topic. In the present work, we proposed to fill this gap by performing a systematic Anatomic Likelihood Estimation meta-analysis of VLSM studies which included tasks traditionally used to assess apraxia. We found that the IPL was crucial for all the tasks. Moreover, lesions within the LOTC were more associated with imitation deficits than tool use or pantomime, confirming its important role in higher visual processing. Our results questioned traditional neurocognitive models on apraxia and may have important clinical implications.
Subjects will be assigned to the recommended dose level determined in dose escalation Phase. Each treatment cycle will be 21 days.
Subjects will receive fostamatinib 100 mg qd, 150 mg qd, or 100 mg bid with dosage determined by the modified continual reassessment method. The treatment period begins at baseline 90 days after transplant and continues for up to 1 year after transplant. In patients with steroid-refractory cGVHD who are also included on this study, these subjects also receive fostamatinib 100mg qd, 150mg qd, or 100mg bid dosage determined by the modified continual reassessment method.
The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
BACKGROUND/AIM: Neskeep®, an absorbable polyglycolic acid spacer, has been developed as the optimal material for spacer placement surgery. However, preventing its severe adhesion is a crucial concern. Therefore, we aimed to identify an effective anti-adhesion agent for Neskeep® using rat models.
MATERIALS AND METHODS: Animal experiments were performed using 60 rats, which underwent Neskeep® placement on the abdominal wall. Three types of anti-adhesion agents were employed, establishing four subgroups: Seprafilm®, INTERCEED®, AdSpray®, and only Neskeep® (control) groups. Rats were sacrificed on postoperative days 7, 14, and 28 to assess adhesion levels around the Neskeep® Macroscopic visual assessment with the Lauder score and histopathological evaluation were performed to assess the degree of adhesion.
RESULTS: There were no significant differences in the proportion of Lauder scores on days 7 and 14 between the four groups. Histological evaluation revealed no significant differences between groups at any observation time. However, the mean Lauder scores at day 28 were 5.0, 1.6, 4.0, and 4.8 in the Neskeep®, Seprafilm®, INTERCEED®, and AdSpray® groups, respectively. The proportion of milder Lauder score was significantly higher in the Seprafilm® group on day 28.
CONCLUSION: Seprafilm® may exhibit an anti-adhesive effect when used with Neskeep®.
Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
This is a single center, observer-blind, randomized, dose-escalating, staggered study with 6 groups: 3 groups of 50 subjects receiving the adjuvanted candidate vaccine, at 3 different doses and 3 groups of 10 subjects receiving the non-adjuvanted candidate vaccine in water for injection, at 3 different doses. The vaccination schedule will be 0-1 month. Blood samples will be collected at 8 visits. The duration of the study will be approximately 14 months for each subject. Rationale for Protocol Posting Amendment: The third vaccination will be cancelled and the visit at Month 7 will be postponed to Month 9. The Protocol Posting has also been updated in order to comply with the FDA Amendment Act, Sep 2007.
PURPOSE:A stable emulsion for a health drink obtained by emulsifying a mixture of tocopherol with a sugar ester. CONSTITUTION:An emulsion for a health drink, containing tocopherol, and obtained by mixing <=60wt% tocopherol with 0.3-40wt% sugar ester, e.g. sucrose acetate isobutyrate, adjusting the specific gravity, adding 40wt% or more aqueous solution of gum arabic, and emulsifying the resultant mixture. The addition of the emulsion to a drink provides a tocopherol emulsion stable for a long term in the drink. The emulsion is useful as a vitamin E raw material for a drink prepared in use without requiring the stability for a long term, or a drink, e.g. a bottled or canned drink, having the stable emulsion state for a long period without causing any ring nor precipitate as the vitamin E raw material.
The patent pertains to a handheld medical device with associated procedures and a system for monitoring medication intake. The device receives, transmits and stores patient journals and controls scheduled alarm times for medication intake. The device records the date and times for medication intake and stores information about confirmed/missed alarms, as well as information about when the indicated compartment was opened/not opened. The device has a personal recording/playback function, individual messages, information about medication side effects and state of health are stored on a memory circuit. The device has a specially adapted patient journal program with two-way communication to the server program. The operating system provides an interface with other external measurement units and journal programs. The device display contains visual symbols, visual illumination, interchangeable audio signals and a vibrator. The electronic signal system with visual indicator emits signals at prescribed intervals. The signal indicates the patient needs to take their medication and the visual illumination indicates the relevant compartment. Missed doses are permanently indicated on the display. Included in the system is a medication receptacle and storage box containing multiple receptacles with adjustable compartments to organise, store and distribute predetermined medications.